⇨ Longtime Biogen exec Alpna Seth has decided to head west, way west, to rejoin ex-Biogen CEO George Scangos as COO of his upstart biotech. He left the big company in July, according to the Boston Business Journal.
⇨ With Eduardo Sanchiz following through on stepping down from the helm at Almirall, the company has recruited a senior Sanofi executive for its new CEO. Peter Guenter has spent the past 22 years at Sanofi, most recently as executive vice president diabetes and cardiovascular global business unit.
⇨ PhRMA has brought in a top clinical research expert — and senior FDA vet — to help guide its lobbying work in Washington, DC. Richard Moscicki is jumping from his post as deputy director for science operations at CDER right over to a new role as chief medical officer at PhRMA, which has been doing its best to spotlight the industry’s multibillion-dollar investment in drug R&D as it seeks a helpful stance from the federal government on a score of key issues. After an internal review that led the group to cut ties with companies that had a less-than-stellar track record in investing in R&D, Moscicki will bring an insider’s knowledge of the agency to his new role leading science and regulatory advocacy efforts
⇨ Christian Meyer is the new chief medical officer at Therachon. Meyer’s resume includes a stint as the CMO at uniQure where he had a helping hand in bringing the world’s most expensive but no longer in production drug Glybera to the market.
⇨ Conatus Pharmaceuticals has bagged Keith Marshall for their EVP-COO-CFO combo gig.
⇨ Karolinska Development’s latest CEO is Viktor Drvota, who replaced Jim Van heusden. Chairman Bo Jesper Hansen also decided to step down and was replaced by board member Niclas Adler.
⇨ Chris Garabedian’s new company Xontogeny has named Fred Callori as SVP of corporate development. Callori is a former partner at Choate Hall & Stewart with experience creating and funding life sciences companies.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 32,300+ biopharma pros who read Endpoints News by email every day.Free Subscription